Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 3, 2020

India approves second Covid-19 vaccine for clinical trials

Zydus Cadila has secured regulatory approval from the Drug Controller General of India (DCGI) to conduct Phase I/II human trials of its Covid-19 vaccine candidate, named ZyCoV-D.

Zydus Cadila has secured regulatory approval from the Drug Controller General of India (DCGI) to conduct Phase I/II human trials of its Covid-19 vaccine candidate, named ZyCoV-D.

This approval comes days after DCGI authorised Bharat Biotech’s Covid-19 vaccine candidate for trials.

Zydus developed the Covid-19 vaccine candidate at its Vaccine Technology Centre in Ahmedabad, India.

In animal studies, the vaccine was able to induce a ‘strong immune response’ in multiple species, including mice, rats, guinea pigs and rabbits.

The antibodies generated were observed to completely neutralise the wild type virus when tested using virus neutralisation assay. This is said to indicate the protective potential of the vaccine.

In repeat dose toxicology studies, no safety concerns were reported for the vaccine candidate administrated via intramuscular, as well as intradermal routes.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Zydus added that up to three times the intended human dose was observed to be safe, well tolerated, and immunogenic in rabbits.

The company has already produced clinical GMP batches of the vaccine candidate, with plans to launch the clinical trials this month in more than 1,000 participants at various sites across India.

Zydus said in a statement: “With ZyCoV-D, the company has successfully established the DNA vaccine platform in the country using non-replicating and non-integrating plasmid carrying the gene of interest, making it very safe.

“The company intends to now rapidly ramp up the production capacities of ZyCoV-D at multiple sites and facilities to cater to Indian and global demand.”

Bharat Biotech received the DCGI approval for its Covid-19 vaccine candidate, Covaxin, to enter Phase I and II studies, which are expected to begin this month.

Covaxin is an inactivated vaccine developed in partnership with the Indian Council of Medical Research (ICMR)’s National Institute of Virology.

ICMR is now working to expedite the trials and contacted 12 institutes to fast track the studies, with an aim to launch the results by 15 August this year.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU